Chemomab Completes Merger with Anchiano Therapeutics (READ MORE) (March 16, 2021)


Investor Relations: Irina Koffler, LifeSci Advisors, LLC

Phone: +1-917-734-7387         

Email: ir@chemomab.com

Chemomab Therapeutics: Sharon Elkobi, VP, Business Development

Phone: +972773310156

Email: bd@chemomab.com

Visit Chemomab online at www.chemomab.com

Neil Cohen | Chief Executive Officer

Mr. Cohen has served as the Chairman and Chief Executive Officer of Castel Partners Ltd. since January 2012. In 1994, he co-founded Israel Seed Partners, a leading venture capital firm, and managed the firm until 2019. Mr. Cohen has invested in and served on the boards of directors of many private technology companies, including a large number which were acquired or completed successful initial public offerings, including Compugen (Nasdaq: CGEN), Shopping.com (Nasdaq: SHOP, acquired by EBAY), Broadlight (acquired by Broadcom, Nasdaq: AVGO) and Cyota (acquired by RSA). He is a venture partner at SKY, an Israeli middle-market private equity firm, at Hetz Ventures Management Ltd., an early-stage Israeli venture capital fund, and Shavit Capital. Mr. Cohen was previously the Business Editor of The Jerusalem Post and began his career in the private equity group at the Rothschild Bioscience Unit of N M Rothschild & Sons Limited in London. Mr. Cohen received a B.A. and M.A., with first class honors, from Oxford University.

Andrew Fine | Chief Financial Officer

Mr. Fine has served as our Chief Financial Officer since July 2020. Mr. Fine has over 20 years of experience in executive financial and operational roles and is currently Co-Managing Director at Line Consulting Ltd. Mr. Fine previously held roles as Chief Financial Officer at Seeking Alpha, ScaleMP and Freightos , leading finance and operations for the companies’ global activities.  Mr. Fine holds a BA and an MBA from the Hebrew University of Jerusalem.